

## Added-Value Licensing Licensing-in on Gene Editing



### THE SITUATION

The client is a leading player in the biotech industry seeking to identify CRISPR-Cas systems based on Cas enzymes alternative to Cas9.

As a first response, the client intended to navigate in the patent landscape for identifying some patent portfolios involving less risk and covering such systems.

In order to achieve this goal the client intended to gain insights based on a deep technological breakdown of patent portfolios combined to the internationally well-known expertise of our patent analysts on this technology.

### OUR APPROACH

As SCBT-Centredoc is one of the worldwide leader of patent analytics on CRISPR (Cf. our media page), we used our monthly updated proprietary RAPID platform. It includes +18k patent families and +430 licensing announcements, that are manually categorized according to 3 technological breakdown and 70 subcategories.

Supplementary patent searches based on biological sequences allowed us to have the best patent analytics results.

Additionally, we conducted technological and legal status analyses on the selected patent portfolio to identify strengths and weaknesses of these ones.

### RESULTS & BENEFITS

Our client obtained a listing of 5 highly relevant player owning strong patent portfolios on CRISPR technologies. For each player, we created an ID card, mentioning key information, including, if any, main licensing announcements or other relevant business news. We also provided in our report strategical and technological recommendations.

A few months after our consulting, our customer signed a licensing-in deal with one of the identified CRISPR players. We also identified one specific player positioned on the exact same segment of interest of our customer, which enabled them to monitor this player.

CONTACT US :

 [biotech@scbt.ch](mailto:biotech@scbt.ch)